Acción SLNO SOLENO THERAPEUTICS, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Soleno Therapeutics, Inc.

Acciones

SLNO

US8342033094

Mercado cerrado - Nasdaq
Otros sitios de cotización
 22:00:00 28/06/2024 		Varia. Cinco días. Varia. 1 de enero.
40,88 USD -2,08 % Gráfico intradía de Soleno Therapeutics, Inc. +0,22 % +1,57 %
28/06 Soleno Therapeutics presenta a la FDA una solicitud de nuevo fármaco para el tratamiento del síndrome de Prader-Willi MT
28/06 Soleno Therapeutics, Inc anuncia la presentación de una solicitud de nuevo fármaco a la FDA estadounidense para los comprimidos de liberación prolongada de DCCR (diazóxido de colina) para el tratamiento del síndrome de Prader-Willi CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Soleno Therapeutics Submits New Drug Application to FDA for Prader-Willi Syndrome Treatment
Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome
Soleno Therapeutics, Inc Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Soleno Therapeutics : June 2024 Corporate Presentation
Soleno Therapeutics to Join Russell 3000 Index
Soleno Therapeutics Set to Join Russell 3000® Index
Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024
Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024
Soleno Therapeutics to Participate in Upcoming Investor Conferences
Soleno Therapeutics Stands with the Prader-Willi Syndrome Community
Soleno Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Soleno Therapeutics Prices $138 Million Stock Offering
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
Soleno Therapeutics Announces Proposed Public Offering of Common Stock
Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome
Soleno Therapeutics, Inc. Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to Natural History of Prader-Willi Syndrome
Soleno Therapeutics' Shares Jump After FDA Grants Breakthrough Designation for Prader-Willi Syndrome Treatment
Soleno Therapeutics Gets Breakthrough Therapy Designation for Diazoxide Choline
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción SLNO
  4. Noticias Soleno Therapeutics, Inc.
  5. Otros idiomas